SG/PUT/NOVO-NORDISK B/550/0.1/20.09.24 | Delayed Deutsche Boerse AG 16:36:07 01/07/2024 BST | ||
| 0.001 EUR | 0.00% |
|
| 6 months | -99.73% | ||
| Current year | -99.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.001 | 0.00% |
| 28/06/24 | 0.001 | 0.00% |
| 27/06/24 | 0.001 | 0.00% |
| 26/06/24 | 0.001 | 0.00% |
| 25/06/24 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 01, 2024 at 04:36 pm
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW3QMC |
| ISIN | DE000SW3QMC2 |
| Date issued | 20/09/2023 |
| Strike | 550 kr |
| Maturity | 20/09/2024 (81 Days) |
| Parity | 10 : 1 |
| Emission price | 0.51 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.56 € |
|---|---|
| Lowest since issue | 0.001 € |
| Delta | 0x |
| Omega | 0.000000 |
| Premium | 0x |
| Gearing | 1167.2x |
| Moneyness | 0.5489 |
| Difference Strike | -454.6 kr |
| Difference Strike % | -82.65% |
| Spread | 0.021 € |
| Spread % | 95.45% |
| Intrinsic value | 0.000000 |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
